Drug intelligence / Profile preview

RK016

Development stage: Preclinical
Lead developer: RevolKa
Modality: Recombinant Proteins and Enzymes
Administration: Peripheral

Overview

RK016 is a protein-based therapeutic candidate currently in development by RevolKa. The drug was discovered and optimized using RevolKa's proprietary protein engineering platform, which utilizes directed evolution to enhance protein properties for therapeutic use. As of the latest pipeline disclosures, RK016 has completed an undisclosed early-stage development milestone. However, the company has not yet revealed the specific molecular target, mechanism of action, or the primary disease indications for this candidate.

Other names: RK016-RevolKa-proteinRK-016-RevolKa-proteinRK 016-RevolKa-protein

Beyond the preview

Go deeper on RK016.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RK016.

Explore the full profile